CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 141 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,018 | -13.0% | 87,097 | 0.0% | 0.06% | -6.8% |
| Q2 2023 | $1,170 | -1.0% | 87,097 | +22.1% | 0.06% | +11.3% |
| Q1 2023 | $1,182 | -11.0% | 71,327 | -0.1% | 0.05% | -17.2% |
| Q4 2022 | $1,328 | -99.9% | 71,400 | -1.4% | 0.06% | +42.2% |
| Q3 2022 | $929,000 | +83.2% | 72,400 | 0.0% | 0.04% | +104.5% |
| Q2 2022 | $507,000 | -15.6% | 72,400 | 0.0% | 0.02% | -8.3% |
| Q1 2022 | $601,000 | -5.2% | 72,400 | -47.3% | 0.02% | +9.1% |
| Q1 2021 | $634,000 | +46.1% | 137,400 | +5.9% | 0.02% | +46.7% |
| Q4 2020 | $434,000 | +11.0% | 129,800 | -1.4% | 0.02% | +15.4% |
| Q3 2020 | $391,000 | -39.4% | 131,600 | -5.7% | 0.01% | -27.8% |
| Q2 2020 | $645,000 | +13.4% | 139,600 | -5.5% | 0.02% | +5.9% |
| Q1 2020 | $569,000 | -3.2% | 147,700 | -5.9% | 0.02% | +30.8% |
| Q4 2019 | $588,000 | -30.2% | 157,000 | -1.1% | 0.01% | -31.6% |
| Q3 2019 | $843,000 | +38.2% | 158,700 | 0.0% | 0.02% | +35.7% |
| Q2 2019 | $610,000 | – | 158,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
| Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
| Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
| CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
| Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
| Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
| AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
| COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
| KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |